The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
The review covered 91 trials involving 107,910 patients, including 60,338 who received a GLP-1 drug and 47,572 who received placebo, it said
a 21% lower likelihood of emergency department visits
50,000+ Reviews From happy Amazon customers REAL RESULTS, REAL CUSTOMERS @iarekitteh Verified Purchase Left is Before
Q7: How can I get a sample to check your quality
doi: 10.1155/2018/1290179 [DOI] [PMC free article] [PubMed] [Google Scholar] 21
